ArticleAIDS (London, England)2013
Association of early HIV viremia with mortality after HIV-associated lymphoma.
Article in AIDS (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Guideline
- Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Trial
- Hodgkin and non-Hodgkin lymphomas in the post-antiretroviral therapy era according to HIV virological suppression.HIV medicine · 2026Observational
- Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.Biomolecules · 2025Review
- Immune reconstitution and evolution of B-cell-stimulating cytokines after R-CHOP therapy for HIV-associated DLBCL.Blood advances · 2024Observational
- HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus.Clinical microbiology reviews · 2024Review
- Treating Cancer in People With HIV.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Virologic Nonsuppression Among Patients With HIV Newly Diagnosed With Cancer at Uganda Cancer Institute: A Cross-Sectional Study.JCO global oncology · 2023Article
- The role of viruses in HIV-associated lymphomas.Seminars in hematology · 2022Article
- Hodgkin Lymphoma in People Living with HIV.Cancers · 2021Review
- Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.Journal for immunotherapy of cancer · 2021Article
- Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting.BMC cancer · 2020Article
- Untangling the Effects of Chemotherapy and HIV on CD4 Counts-Implications for Immunotherapy in HIV and Cancer.JAMA oncology · 2020Article
- CD4/CD8 Ratio and CD4 Nadir Predict Mortality Following Noncommunicable Disease Diagnosis in Adults Living with HIV.AIDS research and human retroviruses · 2019Article
- Why Everyone (Almost) with HIV Needs to Be on Treatment: A Review of the Critical Data.Infectious disease clinics of North America · 2019Review
- Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients.Antiviral therapy · 2019Article
- Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America.Infectious agents and cancer · 2018Article
- Virologic and Immunologic Outcomes in HIV-Infected Patients with Cancer.AIDS research and human retroviruses · 2017Article
- Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria.Infectious agents and cancer · 2017Article
- EBV-dUTPase Modulates Host Immune Responses Potentially Altering the Tumor Microenvironment in EBV-associated Malignancies.Current research on HIV/AIDS · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 1 country.
Funding
Abstract
objectiveTo examine the association between early HIV viremia and mortality after HIV-associated lymphoma.
designMulticenter observational cohort study.
settingCenter for AIDS Research Network of Integrated Clinical Systems cohort.
participantsHIV-infected patients with lymphoma diagnosed between 1996 and 2011, who were alive 6 months after lymphoma diagnosis and with at least two HIV RNA values during the 6 months after lymphoma diagnosis. EXPOSURE: Cumulative HIV viremia during the 6 months after lymphoma diagnosis, expressed as viremia copy-6-months.
main outcome measureAll-cause mortality between 6 months and 5 years after lymphoma diagnosis.
resultsOf 224 included patients, 183 (82%) had non-Hodgkin lymphoma (NHL) and 41 (18%) had Hodgkin lymphoma. At lymphoma diagnosis, 105 (47%) patients were on antiretroviral therapy (ART), median CD4⁺ cell count was 148 cells/μl (interquartile range 54-322), and 33% had suppressed HIV RNA (<400 copies/ml). In adjusted analyses, mortality was associated with older age [adjusted hazard ratio (AHR) 1.37 per decade increase, 95% CI 1.03-1.83], lymphoma occurrence on ART (AHR 1.63, 95% CI 1.02-2.63), lower CD4⁺ cell count (AHR 0.75 per 100 cells/μl increase, 95% CI 0.64-0.89), and higher early cumulative viremia (AHR 1.35 per log₁₀ copies × 6-months/ml, 95% CI 1.11-1.65). The detrimental effect of early cumulative viremia was consistent across patient groups defined by ART status, CD4⁺ cell count, and histology.
conclusionExposure to each additional 1-unit log₁₀ in HIV RNA throughout the 6 months after lymphoma diagnosis was associated with a 35% increase in subsequent mortality. These results suggest that early and effective ART during chemotherapy may improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.